Q2 2025 Earnings Call Transcript July 31, 2025 Biogen Inc. misses on earnings expectations. Reported EPS is $ EPS, ...

Investing.com – Oppenheimer hat die Einstufung "Outperform" und das Kursziel von 205,00 US-Dollar für die Aktie von Biogen (NASDAQ: BIIB) nach der Veröffentlichung der Finanzergebnisse für das zweite ...

We recently published 10 Most Undervalued Pharma Stocks To Buy Now. Biogen Inc. stands sixth on our list among the most ...

Biogen, one of the world's largest biotechnology companies, plans to invest $2 billion and build a new manufacturing facility ...

Investing.com - Truist Securities hat die Beobachtung der Biogen-Aktie (NASDAQ: BIIB) am Montag mit einer "Halten"-Einstufung und einem Kursziel von 142,00 $ aufgenommen. Laut Daten von InvestingPro w ...

In a report released today, George Farmer from Scotiabank maintained a Buy rating on Biogen, with a price target of $224.00. The company’s shares closed yesterday at $130.13. Do ...

In a report released today, David Amsellem from Piper Sandler reiterated a Hold rating on Biogen, with a price target of $115.00. The company’s shares closed yesterday at $130.13. According to ...

CAMBRIDGE, Mass., June 30, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) – announced the initiation of dosing in the global clinical study, PROMINENT. The Phase 3 study will evaluate the ...

Global Phase 3 PROMINENT study will evaluate the efficacy and safety of felzartamab, as compared to tacrolimus, in adults with primary membranous nephropathy (PMN)There are currently no therapies ...